Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Long-term, Prospective, Observational Study to Monitor the Safety and Effectiveness of Ilaris in CAPS Patients

NCT01213641 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT01213641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01213641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Long-term, Prospective, Observational Study to Monitor the Safety and Effectiveness of Ilaris in CAPS Patients
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
November 30, 2009
Completion date
December 31, 2015
Enrollment
288 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

cryopyrin-associated periodic syndromes (caps), familial cold autoinflam syn (fcas), muckle-wells syn (mws), neonatal onset multisystem inflam disease (nomid)